Aimmune Therapeutics Inc. [NASDAQ: AIMT] gained 1.69% or 0.23 points to close at $13.84 with a heavy trading volume of 1627290 shares. The company report on July 30, 2020 that Aimmune Therapeutics Announces Second Quarter 2020 Financial Results and Provides Recent Operational Highlights.
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced financial results for the quarter and six months ended June 30, 2020.
“We are encouraged that an increasing number of allergy practices around the country have re-opened since June. As a result, we have also seen a corresponding inflection in our leading indicator launch metrics. Given this momentum, we have initiated a targeted digital and print marketing campaign to create greater awareness of PALFORZIA among patients and their caregivers in the U.S.,” said Jayson Dallas, M.D., President and Chief Executive Officer of Aimmune Therapeutics. “Our overall business fundamentals and long-term prospects remain strong, and we are confident in the thoughtful manner in which we are navigating this ongoing pandemic.”.
It opened the trading session at $14.40, the shares rose to $14.68 and dropped to $13.61, the range by which the price of stock traded the whole day. The daily chart for AIMT points out that the company has recorded -52.88% loss over the past six months. However, it is still -37.17% lower than its most recent low trading price.
If we look at the average trading volume of 1.13M shares, AIMT reached to a volume of 1627290 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Aimmune Therapeutics Inc. [AIMT]:
Cowen have made an estimate for Aimmune Therapeutics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on July 13, 2020. While these analysts kept the previous recommendation, H.C. Wainwright dropped their target price from $30 to $15. The new note on the price target was released on May 12, 2020, representing the official price target for Aimmune Therapeutics Inc. stock. On February 28, 2020, analysts decreased their price target for AIMT shares from 33 to 30.
The Average True Range (ATR) for Aimmune Therapeutics Inc. is set at 0.80, with the Price to Sales ratio for AIMT stock in the period of the last 12 months amounting to 1599.67. The Price to Book ratio for the last quarter was 5.01, with the Price to Cash per share for the same quarter was set at 4.53.
Trading performance analysis for AIMT stock
Aimmune Therapeutics Inc. [AIMT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.91. With this latest performance, AIMT shares dropped by -20.28% in over the last four-week period, additionally sinking by -52.88% over the last 6 months – not to mention a drop of -27.04% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AIMT stock in for the last two-week period is set at 35.84, with the RSI for the last a single of trading hit 35.46, and the three-weeks RSI is set at 38.14 for Aimmune Therapeutics Inc. [AIMT]. The present Moving Average for the last 50 days of trading for this stock 16.64, while it was recorded at 13.70 for the last single week of trading, and 22.53 for the last 200 days.
Aimmune Therapeutics Inc. [AIMT]: A deeper dive into fundamental analysis
Return on Total Capital for AIMT is now -109.36, given the latest momentum, and Return on Invested Capital for the company is -109.33. Return on Equity for this stock declined to -123.33, with Return on Assets sitting at -91.37. When it comes to the capital structure of this company, Aimmune Therapeutics Inc. [AIMT] has a Total Debt to Total Equity ratio set at 51.73. Additionally, AIMT Total Debt to Total Capital is recorded at 34.09, with Total Debt to Total Assets ending up at 26.33. Long-Term Debt to Equity for the company is recorded at 49.56, with the Long-Term Debt to Total Capital now at 32.66.
Reflecting on the efficiency of the workforce at the company, Aimmune Therapeutics Inc. [AIMT] managed to generate an average of -$903,625 per employee.Aimmune Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.40 and a Current Ratio set at 7.50.
Aimmune Therapeutics Inc. [AIMT]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Aimmune Therapeutics Inc. posted -1.03/share EPS, while the average EPS was predicted by analysts to be reported at -1.03/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AIMT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Aimmune Therapeutics Inc. go to 34.60%.
An analysis of insider ownership at Aimmune Therapeutics Inc. [AIMT]
There are presently around $685 million, or 85.90% of AIMT stock, in the hands of institutional investors. The top three institutional holders of AIMT stocks are: PRICE T ROWE ASSOCIATES INC /MD/ with ownership of 5,192,673, which is approximately -7.645% of the company’s market cap and around 0.90% of the total institutional ownership; VANGUARD GROUP INC, holding 4,137,346 shares of the stock with an approximate value of $57.26 million in AIMT stocks shares; and EVENTIDE ASSET MANAGEMENT, LLC, currently with $53.3 million in AIMT stock with ownership of nearly 24.87% of the company’s market capitalization.
Positions in Aimmune Therapeutics Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 90 institutional holders increased their position in Aimmune Therapeutics Inc. [NASDAQ:AIMT] by around 8,855,211 shares. Additionally, 79 investors decreased positions by around 8,152,236 shares, while 27 investors held positions by with 32,451,523 shares. The mentioned changes placed institutional holdings at 49,458,970 shares, according to the latest SEC report filing. AIMT stock had 37 new institutional investments in for a total of 5,262,422 shares, while 36 institutional investors sold positions of 1,858,036 shares during the same period.